HIV, Buprenorphine, and the Criminal Justice System
| Status: | Active, not recruiting |
|---|---|
| Conditions: | HIV / AIDS, Psychiatric, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | April 2012 |
| End Date: | June 2017 |
As of July, 2014 the study aims have changed. The revised project, called STRIDE2, is a
longitudinal, non-randomized, observational study of individuals living with HIV who are
dependent on opioids. This study is funded by the National Institute on Drug Abuse
(R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason
University, Yale University, and Howard University. Those individuals originally enrolled in
the STRIDE RCT will be followed for 12 months.
longitudinal, non-randomized, observational study of individuals living with HIV who are
dependent on opioids. This study is funded by the National Institute on Drug Abuse
(R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason
University, Yale University, and Howard University. Those individuals originally enrolled in
the STRIDE RCT will be followed for 12 months.
STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide
resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to
examine if there are differences in HIV, drug use, and other outcomes between individuals
receiving treatment versus individuals actively using, not actively using and not in
treatment, and individuals on Methadone, Suboxone, or in some other treatment.
resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to
examine if there are differences in HIV, drug use, and other outcomes between individuals
receiving treatment versus individuals actively using, not actively using and not in
treatment, and individuals on Methadone, Suboxone, or in some other treatment.
Inclusion Criteria:
- HIV+
- Age ≥18 yrs
- Meets DSM-IV criteria for opioid dependence
- Has medical entitlements in DC
- Able to provide informed consent
- Able to communicate in English or Spanish
Exclusion Criteria:
- Being prescribed an opiate medication for a chronic pain condition or expressing the
need to be placed on chronic pain medical conditions for a documented pain condition
- Currently receiving methadone dosing of over 30 mg per day and uninterested in
changing to buprenorphine
- AST and ALT >5x the upper limit of normal (AST≥175, ALT≥195)
- Pregnant or unwilling to use contraception (including OCPs, patch, Depo-Provera,
condoms, etc.)
- Breastfeeding or unwilling to stop breastfeeding
- Subject is part of another pharmacological research study
- Liver dysfunction (acute hepatitis, liver failure or hepatic dysfunction)
- Suicidal ideation
- Hypersensitivity to buprenorphine
We found this trial at
1
site
Click here to add this to my saved trials
